Royal Bank of Canada Decreases Position in AngioDynamics, Inc. $ANGO

Royal Bank of Canada cut its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 34.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 71,872 shares of the medical instruments supplier’s stock after selling 38,125 shares during the period. Royal Bank of Canada owned approximately 0.17% of AngioDynamics worth $817,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Franklin Resources Inc. grew its position in AngioDynamics by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock worth $621,000 after acquiring an additional 1,076 shares during the last quarter. Farther Finance Advisors LLC increased its stake in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the period. Deutsche Bank AG lifted its position in AngioDynamics by 5.9% in the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock valued at $457,000 after purchasing an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in AngioDynamics in the fourth quarter valued at approximately $27,000. Finally, Price T Rowe Associates Inc. MD lifted its position in AngioDynamics by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock valued at $569,000 after purchasing an additional 2,263 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 6.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on ANGO shares. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Finally, HC Wainwright increased their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Stock Down 0.4%

Shares of ANGO stock opened at $15.75 on Friday. The stock has a fifty day moving average of $13.96 and a 200 day moving average of $12.05. AngioDynamics, Inc. has a 52 week low of $9.06 and a 52 week high of $16.29. The firm has a market capitalization of $650.95 million, a price-to-earnings ratio of -18.10 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities research analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.